



COVID-19 Outbreak Control and Prevention State Cell  
Health and Family Welfare Department Govt. of Kerala

**DM Wayanad Institute of Medical Sciences**  
**DM WIMS Virology BSL – 2 Lab**  
ICMR Approved - VBSLDMWIMSK



DM Wayanad Institute of Medical Sciences, Naseera Nagar, Meppadi (P.O), Wayanad -673577, Kerala, India.  
Phone: + 91-8111881053, e-mail: lab@dmwims.com, www.dmwims.com

Laboratory is approved by Indian Council of Medical Research, Government of India through Department of Health and Family Welfare, Government of Kerala.

COVID-19 RT PCR TEST REPORT							
WIMS MRD No				141608			
Date and time of reporting				25.02.2022 06:30PM			
Referred by- Name of facility/self				DM WIMS			
Specimen Details							
Date & Time of Sample Collection				25.02.2022 03.00PM			
Date & Time of Testing				25.02.2022 03.30PM			
Date & Time of Reporting				25.02.2022 06:30PM			
Reporting Details							
Patient ID	SRF ID	Patient name & Address	Age	Sex	Specimen type	Type of test	COVID-19 Result
P- 2180/202 2021632	2180/WYD/ 2022021629	Joe Peter Sebastian Chakkalakal, Kakkavayal (PO), Kalpetta, Wayanad, Kerala	6	Male	Nasal Swab	RT PCR	Negative
Mob: 9003173069							
Prepared by Swapna K Raju Senior Microbiologist							
Checked & Approved by Dr. Deepthy B J Associate Professor, Dept. of Microbiology DM WIMS Virology BSL -2 Lab							

*Note: The results relate only to the specimens tested and should be correlated with clinical findings. Interpretation guidance:*

1. *Negative Result-implies the absence of selective amplification for E gene and N gene in the moment of performing the process, therefore it is considered as Negative result*
2. *Positive Result-implies the selective amplification for E gene and N gene in the moment of performing the process, therefore it is considered as Positive result.*
3. *Test – Quantiplus Version2 ; Negative – No Cq value detected in 40 amplification*
4. *Testing of referred clinical specimens was considered on the basis of request/referral received from/ through state surveillance officer (SSO) of concerned State Integrated Disease Surveillance Programme/any other health care facility affirming requirements of the case definition/s or by self.*
5. *Repeat sampling and testing of lower respiratory specimen is strongly recommended in severe or progressive disease. The repeat specimens may be considered after a gap of 2-4 days after the collection of the first specimen for additional testing if required.*
6. *A positive alternate pathogen does not necessarily rule out either, as little is yet known about the role of coinfections.*
7. *Please note that these results are not to be used for any thesis or presentations or publication in any journal without the prior permission of the Director General, ICMR.*

